

REMARKS

Claims 1-23 have now been cancelled with this response and new claims 24-27 have been added. Applicants have attempted to narrow down the group or specific embodiment as requested in response to the restriction requirement. Unfortunately, the prospective claim set does not correspond exactly to any of the specific groups set forth by the Examiner in the Communication dated April 28, 2003, however, Applicants believe the reduction in claims to be examined and their accompanying scope will assist the Examiner in the examination of the art and of the claimed invention.

Specifically, claim 24 is based upon the method of treatment previously found in claims 2 and 21 but recites a vastly reduced range of chemical structures. Only three of the groups of Formula A are variable and the options for these have been restricted to a small range of related groups. The scope of these structures is only slightly broader than suggested by the Examiner in his proposed Group I. In addition, the medical treatment claim further restricts the claimed matter to methods for the treatment of inflammatory, immune or tissue rejection conditions. This response now gives an independent claim of clear and very limited scope.

Should the Examiner require a single chemical species upon which to begin his examination, we would recommend the species indicated in claim 4, which is the "4-OH-OPB" species shown on page 3 of the originally filed specification.

Applicants, of course, reserve the right to file continuation and divisional applications on the broad subject matter no longer claimed herein.

CONCLUSION

Applicants now believe the application has been put in condition for examination and subsequent allowance. If the undersigned attorney can assist in any matters regarding examination of this case, the Examiner is invited to call at the number listed below.

Respectfully submitted,

DECHERT LLP

Date: _____

July 28, 2003

John W. Ryan

John W. Ryan
Reg. No. 33,771

Dechert LLP
1775 Eye Street, N.W.
Washington, D.C. 20006
Telephone (202) 261-3375
Fax (202) 261-3333